Pharmaceutical Packaging: How Biologics and GLP-1 Pens Are Building a USD 275.6 Billion Market
Executive summary. Pharmaceutical packaging protects medicines from contamination, light, moisture and tampering, keeps them stable until use and helps patients take the right dose. It ranges from bottles and blister packs to glass vials, cartridges and prefilled syringes. Biologics, injectable weight-loss and diabetes drugs, anti-counterfeiting rules and sustainability targets are raising both the complexity and the value of each pack. Strategic Revenue Insights estimates the global pharmaceutical packaging market at USD 118.2 billion in 2024, rising to USD 275.6 billion by 2033. Drug safety and compliance needs, chronic disease and ageing populations, pharmaceutical growth in emerging markets, smart packaging and growth in biologics are driving it. This article sets out five lessons from the packaging makers, drug companies and contract packagers moving first, with takeaways for strategy, product, operations, channels and revenue.
The structure of the market shows where value is concentrating. Strategic Revenue Insights' Pharmaceutical Packaging Market research finds that plastic is the dominant material while glass grows for injectables and biologics, that bottles are the most widely used product while vials, ampoules and blister packs show significant demand, and that pharmaceutical manufacturers are the dominant end users, with contract packaging also significant. Asia Pacific leads the market. The research names stringent regulation, the cost of advanced packaging and counterfeit drugs as challenges, and lists Amcor, Gerresheimer, Berry Global, West Pharmaceutical Services, Schott, AptarGroup, Catalent and Becton Dickinson among the key companies.
Injectable drugs are pulling demand toward high-value formats. SCHOTT Pharma reported fiscal 2025 revenue of EUR 986.2 million, with high-value solutions such as prefillable syringes and cartridges reaching 57 percent of revenue, and cited strong demand for sterile cartridges for biologics and GLP-1 therapies, according to the company.
Why the Pharmaceutical Packaging Market Is Entering a New Phase
Three structural forces are converging.
Biologics and injectables need better containers. Proteins, vaccines and GLP-1 drugs are sensitive to the materials they touch. SRI's research names growth in biologics and specialty drugs as a driver and notes that glass is growing for injectables and biologics. The demand behind weight-loss injectables is explored in how obesity pills are reshaping GLP-1 drugs.
Traceability and anti-counterfeiting are mandatory. Serialisation rules in the United States, Europe and other markets require unique codes and tamper evidence. SRI's research names counterfeit drugs as a threat and smart packaging with RFID and QR codes as a driver.
Sustainability reaches the pharmacy. Drug companies have climate targets, and packaging is a visible source of waste. SRI's research lists sustainable and recyclable materials as an opportunity, while safety rules limit how fast materials can change.
These forces explain SRI's forecast of strong growth to 2033, with value concentrating in injectable formats, smart packaging and Asia Pacific.
Five Lessons From the Companies Moving First
The packaging makers and drug companies turning these forces into advantage share a recognisable pattern. We have distilled it into five lessons, each followed by a takeaway for a specific leadership function.
Lesson 1: Move Up to High-Value Formats
Standard bottles and blister packs are large but competitive. Prefillable syringes, cartridges for pens and autoinjectors, ready-to-use sterile vials and specialised closures command higher prices and longer contracts, because switching them requires new regulatory filings.
The companies moving first shift their mix toward these formats and build long-term supply agreements with drug makers, as SCHOTT Pharma's growing share of high-value solutions shows.
"In pharmaceutical packaging, the container is now part of the drug. Once a pack is approved, the customer rarely changes it."
Takeaway on strategy. Shift the portfolio toward prefillable syringes, cartridges and ready-to-use sterile formats, and secure multi-year supply agreements with drug makers.
Lesson 2: Design for Patients and Devices
Many new drugs are taken at home by patients, often by injection. Packaging and delivery devices must be easy to use, reduce errors and support adherence. SRI's research names patient compliance as a driver.
The companies moving first co-design containers with pen and autoinjector makers, add dose tracking and connected features where useful and design blister packs and bottles for older patients and child safety.
Takeaway on product. Co-design containers with drug delivery devices, build patient-friendly and connected features, and design for home use, older patients and child safety.
Lesson 3: Capacity and Quality Are Strategic
Injectable packaging requires clean rooms, precise glass and polymer forming and strict inspection. Building that capacity takes years, and demand from biologics and GLP-1 drugs can shift quickly. SCHOTT Pharma cited ramp-up costs at its new prefillable syringe plant and a revised customer outlook for fiscal 2026, showing both the opportunity and the risk.
The companies moving first add capacity in step with customer contracts, invest in automated inspection and maintain flexible lines across formats. Sterile supply chain thinking, as in why aseptic packaging is becoming the backbone of the shelf-stable supply chain, applies directly.
"In injectable packaging, a single particle can stop a batch. Quality systems are the real capacity."
Takeaway on operations. Add sterile capacity in line with signed contracts, automate inspection, and keep lines flexible across vials, cartridges and syringes.
Lesson 4: Partner Across the Drug Supply Chain
SRI's research identifies pharmaceutical manufacturers as the dominant end users, with contract packaging significant and pharmacy channels growing. Drug makers increasingly outsource packaging to contract development and manufacturing organisations, and serialisation links packaging to distributors and pharmacies.
The companies moving first partner with drug makers from clinical development, with contract manufacturers for fill-finish and with distributors for traceability. Temperature-sensitive drugs also depend on automation in pharma cold chain logistics.
Takeaway on channels. Engage drug makers from clinical development, partner with contract manufacturers and fill-finish providers, and support serialisation with distributors and pharmacies.
Lesson 5: Asia Pacific Leads
SRI's research identifies Asia Pacific as the leading region, with China and India showing high growth among the countries it lists. Expanding generic and biologics production, contract manufacturing and growing healthcare access drive demand. The United States remains the largest single country market listed.
The capabilities that decide who captures this demand are specific:
A portfolio weighted toward high-value injectable formats.
Patient-friendly and device-compatible designs.
Sterile capacity and automated quality systems.
Partnerships across drug makers, contract manufacturers and distributors.
Local production in Asia Pacific and the United States.
Companies evaluating these competitive dynamics in greater detail can use SRI's Pharmaceutical Packaging Market analysis to assess material, product and end-user segments and the positioning of the leading suppliers.
Takeaway on market development. Build capacity in India and China for generics and contract manufacturing, and supply injectable formats to growing regional biologics producers.
Where the Opportunity Is Concentrating
Value is moving toward injectable formats, smart packaging and Asia Pacific.
By material, plastic dominates while glass grows for injectables and biologics.
By product, bottles are the most widely used, while vials, cartridges and syringes rise in value.
By end user, pharmaceutical manufacturers dominate and contract packaging is significant.
By geography, Asia Pacific leads. Recyclable designs from the flexible packaging shift are starting to reach secondary pharmaceutical packs.
At the Horizon: What to Watch Over the Next Three Years
Injectable demand. Growth in biologics and GLP-1 drugs, and the shift toward oral GLP-1 pills, will shape demand for cartridges and syringes.
Serialisation enforcement. Full enforcement of traceability rules will raise demand for smart labels and verification.
Sustainable materials. Approval of recyclable and lower-carbon materials for primary packaging will decide how fast sustainability reaches medicines.
"The next phase of pharmaceutical packaging will be won by the companies that keep complex drugs safe, traceable and easy for patients to use."
The Strategic Revenue Opportunity
For packaging makers, the task is to move up to high-value formats with secure contracts. For drug makers, the opportunity lies in packaging that improves adherence and supply security. For contract manufacturers, the priority is integrated fill-finish and packaging. For investors, the signal is high-value revenue share, contract length and capacity utilisation.
Market intelligence turns these questions into decisions. Segment-level sizing shows where material, product and end-user demand is concentrating, competitive analysis shows how suppliers are positioned, and regional analysis shows where pharmaceutical production will pull growth first. This is the path from market signals to strategic insight to revenue impact.
Takeaway on revenue. Treat the pharmaceutical packaging market as four revenue pools: standard oral packaging sold on cost and compliance, injectable containers sold under long-term contracts, smart and serialised packaging sold on security, and design and regulatory services sold to drug makers. Each needs its own pricing model.
The Next Leg: Preparing for the Journey Ahead
The defining shift in pharmaceutical packaging is that the pack has become part of the therapy. That changes how containers are designed, approved and supplied. The companies moving first are not the ones with the most bottles; they are the ones moving up to high-value formats, designing for patients, investing in sterile capacity, partnering across the supply chain and expanding where growth is fastest.
The next three years will decide which suppliers become the default partners for biologics and injectable medicines. Decision-makers should invest in injectable formats, quality systems and partnerships and track injectable demand, serialisation and sustainable materials. Companies evaluating growth opportunities in this market can use Strategic Revenue Insights' Pharmaceutical Packaging Market report to assess market size, competitive dynamics, regional opportunities and strategic growth priorities.
Sources: Strategic Revenue Insights, Pharmaceutical Packaging Market report (2026); SCHOTT Pharma fiscal year 2025 results.
Frequently Asked Questions
How big is the pharmaceutical packaging market?
Strategic Revenue Insights estimates the global pharmaceutical packaging market at USD 118.2 billion in 2024, rising to USD 275.6 billion by 2033. Asia Pacific leads the market, plastic is the dominant material and pharmaceutical manufacturers are the largest end users.
What is driving growth in pharmaceutical packaging?
Demand for packaging that supports drug safety, shelf life and patient compliance, chronic disease and ageing populations, pharmaceutical expansion in emerging markets, smart packaging for traceability and growth in biologics and specialty drugs are the main drivers of pharmaceutical packaging growth.
Why is glass packaging growing for medicines?
Glass is growing for injectables and biologics, according to Strategic Revenue Insights, because sensitive drugs need inert, high-quality containers such as vials, cartridges and prefillable syringes. Demand from biologics and GLP-1 therapies is pushing suppliers toward these high-value formats.
What are the main challenges in pharmaceutical packaging?
The main challenges are stringent regulation from agencies such as the FDA and EMA, the high cost of advanced packaging, which is a barrier for smaller companies, and the threat of counterfeit drugs, which requires serialisation and tamper-evident designs.
About the authors: This article was prepared by the Strategic Revenue Insights research team, which combines market intelligence, competitive analysis and strategic advisory for growth-stage, mid-market and enterprise organisations across the packaging sector.
Sector analyst: Thomas Müller, Head of Sustainability Intelligence. Our market estimates combine primary research (interviews, surveys and expert panels) with secondary data (industry reports, databases and public disclosures); read more about how Strategic Revenue Insights works. To discuss this market with our analysts, contact our team.
Comments